Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM

Sponsor
Zhongda Hospital
Study ID
NCT06447727
Status
Unknown

Conditions

  • Colorectal Cancer Metastatic

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SIRT with Yttrium-90 Microspheres — DRUG
    Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
  • FOLFIRI and Bevacizumab — DRUG
    FOLFIRI and Bevacizumab

Study Details

To observe the PFS of yttrium \[90Y\] microsphere injection combined with FOLFIRI and bevacizumab in second-line treatment of CRLM.

Key Dates

First listed
Jun 7, 2024
Start date
May 20, 2024
Status verified
Jun 2024
Primary completion
Nov 30, 2025
Completion
Nov 30, 2025

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: SIRT with Yttrium-90 Microspheres combined with FOLFIRI and Bevacizumab
    Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection combined with FOLFIRI and Bevacizumab

Primary Outcome Measure

Progression-Free Survival(PFS) [ Time Frame: until death or 18 months after treatment with yttrium [90Y] microspheres, whichever occurred first. ]

Central Contacts

Related Studies